SI2817407T1 - Oligonucleotides for modulating gene expression and their use - Google Patents

Oligonucleotides for modulating gene expression and their use Download PDF

Info

Publication number
SI2817407T1
SI2817407T1 SI201330845T SI201330845T SI2817407T1 SI 2817407 T1 SI2817407 T1 SI 2817407T1 SI 201330845 T SI201330845 T SI 201330845T SI 201330845 T SI201330845 T SI 201330845T SI 2817407 T1 SI2817407 T1 SI 2817407T1
Authority
SI
Slovenia
Prior art keywords
oligonucleotide
gene
seq
nucleotide
tumor
Prior art date
Application number
SI201330845T
Other languages
English (en)
Slovenian (sl)
Inventor
Roberto Tonelli
Leonardo Venturelli
Andrea Tortori
Luca Montemurro
Original Assignee
Biogenera S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogenera S.P.A. filed Critical Biogenera S.P.A.
Publication of SI2817407T1 publication Critical patent/SI2817407T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
SI201330845T 2012-02-24 2013-02-21 Oligonucleotides for modulating gene expression and their use SI2817407T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000275A ITMI20120275A1 (it) 2012-02-24 2012-02-24 Oligonucleotidi per la modulazione dell'espressione genica e loro usi
PCT/IB2013/051410 WO2013124807A2 (en) 2012-02-24 2013-02-21 Oligonucleotides for modulating gene expression and uses thereof
EP13716415.8A EP2817407B1 (en) 2012-02-24 2013-02-21 Oligonucleotides for modulating gene expression and uses thereof

Publications (1)

Publication Number Publication Date
SI2817407T1 true SI2817407T1 (en) 2018-01-31

Family

ID=45999941

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201330845T SI2817407T1 (en) 2012-02-24 2013-02-21 Oligonucleotides for modulating gene expression and their use

Country Status (28)

Country Link
US (2) US10023867B2 (enExample)
EP (1) EP2817407B1 (enExample)
JP (2) JP6333739B2 (enExample)
KR (1) KR101992925B1 (enExample)
CN (2) CN104169421A (enExample)
AR (1) AR090129A1 (enExample)
AU (2) AU2013223694B2 (enExample)
BR (1) BR112014020885B1 (enExample)
CA (1) CA2864060C (enExample)
CY (1) CY1120084T1 (enExample)
DK (1) DK2817407T3 (enExample)
ES (1) ES2651147T3 (enExample)
HK (1) HK1201878A1 (enExample)
HU (1) HUE034846T2 (enExample)
IN (1) IN2014MN01493A (enExample)
IT (1) ITMI20120275A1 (enExample)
LT (1) LT2817407T (enExample)
MA (1) MA35935B1 (enExample)
NO (1) NO2817407T3 (enExample)
PL (1) PL2817407T3 (enExample)
PT (1) PT2817407T (enExample)
RS (1) RS56631B1 (enExample)
RU (1) RU2648140C2 (enExample)
SG (2) SG11201404852WA (enExample)
SI (1) SI2817407T1 (enExample)
SM (1) SMT201800042T1 (enExample)
TN (1) TN2014000327A1 (enExample)
WO (1) WO2013124807A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20120275A1 (it) * 2012-02-24 2013-08-25 Biogenera Societa A Responsabilita Limitata Oligonucleotidi per la modulazione dell'espressione genica e loro usi
US10174315B2 (en) 2012-05-16 2019-01-08 The General Hospital Corporation Compositions and methods for modulating hemoglobin gene family expression
CN104540946A (zh) 2012-05-16 2015-04-22 Rana医疗有限公司 用于调节utrn表达的组合物和方法
CN104583402A (zh) 2012-05-16 2015-04-29 Rana医疗有限公司 用于调节mecp2表达的组合物和方法
JP2015523854A (ja) 2012-05-16 2015-08-20 ラナ セラピューティクス インコーポレイテッド Ｓｍｎ遺伝子ファミリー発現を調節するための組成物及び方法
EA201492120A1 (ru) 2012-05-16 2015-10-30 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии atp2a2
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
JP6811338B2 (ja) * 2016-12-13 2021-01-13 エーエム サイエンシーズ インコーポレイテッド Ｂ型肝炎の予防または治療用医薬組成物
EP4497432A4 (en) * 2022-03-22 2025-07-30 Bion Inc PROTEIN DELIVERY COMPOSITION CONTAINING BILE SALT AND CATIONIC PEPTIDE AND USE THEREOF

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2300938A1 (en) * 1997-08-20 1999-02-25 Somagenics, Inc. Antisense and antigene therapeutics with improved binding properties and methods for their use
WO2001061030A2 (en) * 2000-02-14 2001-08-23 Bollon Arthur P LIBRARIES OF OPTIMUM SUBSEQUENCE REGIONS OF mRNA AND GENOMIC DNA FOR CONTROL OF GENE EXPRESSION
JP2004524371A (ja) * 2001-04-13 2004-08-12 ザ・ポピュレイション・カウンシル，インコーポレイテッド 核レセプターを介するペプチド核酸の細胞核内導入
US20030087861A1 (en) * 2001-05-17 2003-05-08 Iversen Patrick L Combined approach to treatment of cancer using a c-myc antisense oligomer
EP1448590A4 (en) * 2002-02-20 2004-12-15 Sirna Therapeutics Inc Inhibition of the myc and myb genes mediated by RNA interference mediated or genes of the corresponding synthetic pathways
ITMI20030860A1 (it) * 2003-04-29 2004-10-30 Univ Bologna Metodo per l'inibizione selettiva del gene n-myc
WO2005045032A2 (en) 2003-10-20 2005-05-19 Sima Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF EARLY GROWTH RESPONSE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050287667A1 (en) * 2004-06-01 2005-12-29 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
GB0415263D0 (en) * 2004-07-07 2004-08-11 Norwegian Radium Hospital Res Method
US20090202565A1 (en) * 2004-10-25 2009-08-13 Mark Aron Labow Torc polynucleotides and polypeptides and method of use
US20090324587A1 (en) * 2005-12-01 2009-12-31 Neal Clifford Goodwin Cancer Therapies and Pharmaceutical Compositions Used Therein
US7625874B2 (en) * 2006-04-11 2009-12-01 The Regents Of The University Of California Compositions and methods for treating diseases associated with T-box and N-Myc
US20080038783A1 (en) * 2006-06-29 2008-02-14 Applera Corporation Compositions and Methods Pertaining to Guanylation of PNA Oligomers
US20090047295A1 (en) 2007-07-12 2009-02-19 Berry David A Methods and Compositions for Reducing Stemness in Oncogenesis
JP2011511051A (ja) * 2008-02-05 2011-04-07 アンティソマ リサーチ リミテッド 生物学的物質およびそれらの使用
KR20110091796A (ko) * 2008-12-04 2011-08-12 오피케이오 큐알엔에이, 엘엘씨 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
CN102058535B (zh) * 2010-12-21 2013-05-01 中国人民解放军总医院 叶酸受体靶向的新型脂质体
ITMI20120275A1 (it) * 2012-02-24 2013-08-25 Biogenera Societa A Responsabilita Limitata Oligonucleotidi per la modulazione dell'espressione genica e loro usi

Also Published As

Publication number Publication date
SMT201800042T1 (it) 2018-03-08
BR112014020885A2 (pt) 2018-01-09
IN2014MN01493A (enExample) 2015-04-17
CA2864060C (en) 2020-03-10
JP6333739B2 (ja) 2018-05-30
US10023867B2 (en) 2018-07-17
NO2817407T3 (enExample) 2018-02-03
MA35935B1 (fr) 2014-12-01
HUE034846T2 (en) 2018-03-28
AU2018278972A1 (en) 2019-01-17
TN2014000327A1 (en) 2015-12-21
CA2864060A1 (en) 2013-08-29
PT2817407T (pt) 2017-12-07
ITMI20120275A1 (it) 2013-08-25
KR101992925B1 (ko) 2019-06-25
CN104169421A (zh) 2014-11-26
CY1120084T1 (el) 2018-12-12
BR112014020885B1 (pt) 2020-10-27
WO2013124807A3 (en) 2013-12-27
PL2817407T3 (pl) 2018-03-30
DK2817407T3 (en) 2017-12-18
US10752900B2 (en) 2020-08-25
EP2817407A2 (en) 2014-12-31
HK1201878A1 (en) 2015-09-11
CN115216475A (zh) 2022-10-21
AU2013223694B2 (en) 2019-01-03
SG11201404852WA (en) 2014-10-30
ES2651147T3 (es) 2018-01-24
AU2013223694A1 (en) 2014-09-25
RU2014138198A (ru) 2016-04-10
LT2817407T (lt) 2018-01-25
AR090129A1 (es) 2014-10-22
RU2648140C2 (ru) 2018-03-22
WO2013124807A2 (en) 2013-08-29
SG10201606946YA (en) 2016-10-28
EP2817407B1 (en) 2017-09-06
JP2018078893A (ja) 2018-05-24
JP2015513398A (ja) 2015-05-14
US20180282731A1 (en) 2018-10-04
RS56631B1 (sr) 2018-03-30
KR20140130514A (ko) 2014-11-10
US20160040166A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
JP2015513398A5 (enExample)
JP7645323B2 (ja) Ｂ型肝炎感染の治療方法
RU2014138198A (ru) Олигонуклеотиды для модулирования экспресии генов и их применения
CN113748208A (zh) 用于抑制中枢神经系统中的基因表达的组合物和方法
DK3135301T3 (en) OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC SUBSTANCES FOR NUCLEIC ACID CONJUGATES
AU2024203138A1 (en) Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
HRP20210612T1 (hr) Postupci i pripravci za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk
CA2872304C (en) Organic compositions to treat kras-related diseases
CN116096889A (zh) 用于抑制angptl3表达的组合物和方法
JP2021533804A5 (enExample)
WO1996032474A1 (en) Cooperative oligonucleotides
SI2929031T1 (en) PCSK9 IRNA assemblies and procedures for their use
CA3153026A1 (en) Chemical modifications of small interfering rna with minimal fluorine content
EP3883581A1 (en) Compositions and methods for inhibiting hmgb1 expression
CA2916989A1 (en) Inhibition of microrna for treatment of sepsis
JP2013530685A5 (enExample)
WO2022272108A2 (en) Products and compositions
EP3740248A1 (en) Methods and compositions for treating bile duct paucity-associated conditions
Barker Jr et al. Plasmodium falciparum: Effect of Chemical Structure on Efficacy and Specificity of Antisense Oligonucleotides against Malariain Vitro
AU2003236659B2 (en) Cooperative oligonucleotides
WO1997038097A1 (en) Cooperative oligonucleotides
JP2026078993A (ja) 標的ヌクレオチド配列の改変のための二本鎖ヌクレオチド複合体
AU2003236659A1 (en) Cooperative oligonucleotides